Upcoming Events
  1. Consumer training workshops

    July 17 @ 12:30 pm - 2:00 pm
  2. Conducting systematic reviews: A short course for thoracic oncology nurses

    August 5 @ 6:30 pm
  3. 6th ALTG Lung Cancer Preceptorship

    October 23 @ 10:00 am - October 24 @ 3:30 pm
  4. ALTG open MAC and SAC meetings

    November 20

Thoracic oncology highlights from ASCO2020 webinar- recording and evaluation survey

Please fill in the evaluation survey if you have not already done so by clicking on the survey icon at the base of your webinar console.

Please access the recording and evaluation survey here

ALTG awarded $12 million in funding

The ALTG is pleased to announce over $12 million in funding has been successfully awarded to ALTG, NHMRC Clinical Trial Centre and the Australian Genomic Cancer Medicine Centre for the ASPiRATION project. In this ground-breaking precision medicine study, led by ALTG President A/Prof Nick Pavlakis and ALTG Scientific Advisory Committee Chair, Prof Ben Solomon, ASPiRATION will explore the benefit of routine comprehensive genomic profiling in 1000 newly-diagnosed metastatic, non-squamous, NSCLC patients in Australia. The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.

Revised Scientific Advisory Committee Structure and Call for Co-Chairs

The ALTG is growing and, as clinical research in lung and other thoracic cancers increases, the environment in which we operate is becoming more complex and competitive. To meet this challenge we need to be able to act quickly to generate ideas and develop them into sound trial concepts whilst maintaining academic standards. At its meeting in February the Management Advisory Committee (MAC) reviewed and made some adjustments to the Scientific Advisory Committee (SAC) structure to ensure it is appropriate for the group’s needs. An overview of the group’s trial development process and SAC structure can be found here.

SAC Subgroups

Five SAC Subgroups will be responsible for generating and developing trial concepts for SAC review in different clinical settings. The formalisation of SAC Subgroups is an extension of the way in which the group has worked in the past, when breakout groups have met at workshops. SAC Subgroups will be formed by members with an interest in the particular clinical setting, led by two Co-Chairs and supported by a Research Fellow and the ALTG Secretariat within the Lung Foundation. Subgroup Co-Chairs are responsible for ensuring the subgroups operate effectively to generate and develop clinical trial concepts to the point where they are suitable for SAC consideration. Subgroup Co-Chairs (one per subgroup) will also participate on the SAC. Please contact Ros to express your interest in joining and/or Chairing one of these SAC Subgroups..

  • Early Diagnosis
  • NSCLC
  • Mesothelioma
  • SCLC
  • Supportive/Palliative Care

SAC Executive

A SAC Executive will meet between the scheduled quarterly SAC meetings and at other times, as needed, to facilitate decision-making and maintain momentum around developing trial concepts. The SAC Executive comprises:

  • SAC Chair OR Deputy Chair
  • ALTG President OR Past-President
  • SAC Subgroup Chairs (one per subgroup, based on the meeting agenda)
  • Data Centre Representative
  • Research Fellow (based on meeting agenda)
  • ALTG Executive Officer

SAC Composition

To reflect these changes, the SAC now comprises the following members:

  • SAC Chair
  • SAC Deputy Chair
  • ALTG President
  • ALTG Past-President
  • SAC Subgroup Chairs (one per subgroup)
  • Consumer Advisory Panel (CAP) Representatives (2)
  • Data Centre Representative
  • ALTG Executive Officer
  • Research Fellows (ex-officio)

Additional members may be co-opted to the SAC and/or SAC Executive based on the meeting agenda.